Pro-Dex, Inc. (NASDAQ:PDEX) Director Raymond E. Cabillot Sells 1,200 Shares

Pro-Dex, Inc. (NASDAQ:PDEX - Get Free Report) Director Raymond E. Cabillot sold 1,200 shares of the firm's stock in a transaction that occurred on Friday, January 10th. The stock was sold at an average price of $47.76, for a total value of $57,312.00. Following the sale, the director now directly owns 359,646 shares of the company's stock, valued at $17,176,692.96. This represents a 0.33 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Pro-Dex Stock Down 3.7 %

Pro-Dex stock traded down $1.74 during midday trading on Tuesday, reaching $45.00. The stock had a trading volume of 15,511 shares, compared to its average volume of 31,039. The company has a fifty day moving average price of $48.12 and a two-hundred day moving average price of $32.49. Pro-Dex, Inc. has a 12 month low of $16.18 and a 12 month high of $59.60. The company has a current ratio of 3.41, a quick ratio of 1.94 and a debt-to-equity ratio of 0.36. The company has a market capitalization of $146.66 million, a P/E ratio of 29.22 and a beta of 0.56.

Analysts Set New Price Targets

PDEX has been the topic of a number of research analyst reports. Ascendiant Capital Markets increased their price target on Pro-Dex from $30.00 to $52.00 and gave the stock a "buy" rating in a report on Monday, November 11th. StockNews.com raised shares of Pro-Dex from a "buy" rating to a "strong-buy" rating in a research note on Saturday, December 14th.

Institutional Investors Weigh In On Pro-Dex

Hedge funds and other institutional investors have recently modified their holdings of the company. Renaissance Technologies LLC raised its stake in shares of Pro-Dex by 7.9% in the second quarter. Renaissance Technologies LLC now owns 12,240 shares of the medical instruments supplier's stock worth $240,000 after purchasing an additional 900 shares during the last quarter. FMR LLC lifted its stake in Pro-Dex by 34.9% during the 3rd quarter. FMR LLC now owns 3,973 shares of the medical instruments supplier's stock valued at $119,000 after acquiring an additional 1,028 shares in the last quarter. Geode Capital Management LLC boosted its holdings in Pro-Dex by 9.1% during the 3rd quarter. Geode Capital Management LLC now owns 27,435 shares of the medical instruments supplier's stock worth $819,000 after acquiring an additional 2,296 shares during the last quarter. Dimensional Fund Advisors LP grew its stake in shares of Pro-Dex by 5.1% in the 2nd quarter. Dimensional Fund Advisors LP now owns 63,036 shares of the medical instruments supplier's stock worth $1,238,000 after acquiring an additional 3,067 shares in the last quarter. Finally, Bard Associates Inc. raised its holdings in shares of Pro-Dex by 17.6% in the third quarter. Bard Associates Inc. now owns 13,596 shares of the medical instruments supplier's stock valued at $406,000 after purchasing an additional 2,031 shares during the last quarter. Institutional investors own 15.28% of the company's stock.

About Pro-Dex

Pro-Dex, Inc designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.